Optical Metamaterial Biosensors, Detection Instruments, and Assays for Point of Care Cancer Molecular Diagnostics

Join the live event on Wed, 4 November 2026 at 15:00 (GMT) or watch the recording on demand afterwards.

Published in Physics

Optical Metamaterial Biosensors, Detection Instruments, and Assays for Point of Care Cancer Molecular Diagnostics

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Seminar | Series


Speakers

  • Prof. Dr Chris D. Geddes FRSC — University of Maryland, Baltimore County
  • Prof. Brian T. Cunningham — University of Illinois Urbana-Champaign

Abstract

Next-generation technologies for genomic sequencing and proteome profiling are revealing the mechanisms of cancer biology, while generating panels of molecular biomarkers that characterize the stage and mechanisms driving disease within individual patients. While “liquid biopsy” samples can be obtained noninvasively and analyzed in centralized laboratory facilities, several clinical and human-centric factors motivate the need to perform cancer molecular diagnostics at the point of care, where obtaining immediate results in settings such as the oncologist’s office can inform initial therapy selection, therapy effectiveness monitoring, and longitudinal monitoring. Enabling such a vision requires development of novel sample preparation, assay methods, and biosensor detection that provides simple and rapid workflows performed on minimally processed samples, miniature and inexpensive detection instrumentation, low detection limits, quantitative accuracy, and multiplexing that incorporates experimental controls. This talk will summarize recent efforts to develop digital-resolution biodetection that utilizes photonic crystal surfaces and nanoparticle tags to amplify molecular detection contrast while utilizing novel biochemistry methods and machine-learning based image processing to detect nucleic acid and protein cancer biomarkers. Utilizing simple one-pot, room temperature assay workflows with <30 minute sample-to-answer time and detection with a ~$1K instrument, we are demonstrating attomolar-level detection limits with high selectivity in serum.

Looking for more in the field?

Explore more events from Springer Nature Biophysics Seminars and Springer Nature's Physics.

Follow the Topic

Biophysics
Physical Sciences > Physics and Astronomy > Biophysics

Related Collections

With Collections, you can get published faster and increase your visibility.

Bioenergetic phenotypes in metabolic genetic diseases

Inherited diseases represent a vast group of pathologies resulting from variants in specific genes encoding different proteins, which directly or indirectly affect metabolic pathways or impair mitochondrial and cellular functions. Thus, genetic diseases, depending on which gene is involved, may generate subtle, mild, or severe metabolic phenotypes, caused by enzyme malfunction, structural or functional alterations in proteins or cofactors, or disruptions in cellular signaling or transport mechanisms. The consequences of deranged metabolic pathways can include: - The accumulation of compounds that may become toxic; - A deficiency or absence of the final products of metabolic pathways, leading to a shortage of essential substrates or disruptions in energy production; - The activation of alternative metabolic pathways, potentially producing secondary metabolites that are normally absent and may also be toxic. Emerging literature shows that bioenergetic defects, characterized by reduced energy availability or increased oxidative stress, lead to profound changes in fundamental processes such as mitochondrial biogenesis, mitophagy, and mitochondria–endoplasmic reticulum communication, with pathological consequences at both the cellular and organismal levels.

This Special Collection invites original research articles, reviews, and perspectives aimed at elucidating the mechanistic links between genetic variants and bioenergetic dysfunction. Contributions addressing how specific mutations directly or indirectly impact energy production systems, as well as studies exploring molecular and metabolic pathway alterations associated with these defects, are particularly encouraged.

Depending on where you are located, you may be able to publish open access at no additional cost to you. Researchers at many institutions such as Italy, France, Portugal, Spain, Germany and United Kingdom can publish open access in the journal at no additional cost.

Check your eligibility prior to submission here: Open access funding | Journal of Bioenergetics and Biomembranes | Springer Nature Link

Publishing Model: Hybrid

Deadline: Dec 31, 2026

Plasmon-enhanced sensing and catalysis

Plasmon-enhanced sensing and catalysis harnesses the unique light-matter interactions of metallic nanostructures to enable high-sensitivity detection and efficient chemical transformations. This special collection invites contributions that advance the fundamental understanding and practical application of plasmonic effects, including but not limited to:

1. Novel plasmonic materials and nanostructures for enhanced spectroscopic sensing (SERS, TERS, SEIRA, enhanced fluorescence, etc.)

2. Plasmon-enhanced fluorescence for bioimaging, immunoassays, and molecular detection

3. Plasmonic biosensing (e.g., LSPR-based biosensors, fiber-optic plasmonic sensors, point-of-care devices)

4. Plasmon-driven and plasmon-mediated catalytic reactions

5. Hot carrier dynamics and energy transfer mechanisms

6. Hybrid plasmonic–photonic, plasmonic–2D material or wearable systems

7. Single-particle and single-molecule sensing

8. Plasmon-enhanced electrochemistry and photocatalysis

9. Theoretical and computational modelling of plasmonic enhancement

10. Emerging applications in biological analysis, environmental monitoring, and energy conversion

Both original research articles and comprehensive reviews are welcome. Studies that bridge experimental and theoretical approaches, or that demonstrate significant advances in sensitivity, selectivity, or catalytic efficiency, are particularly encouraged.

Publishing Model: Hybrid

Deadline: Mar 31, 2027